Martingale Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Martingale Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-252	Closed	-$87K	–	1039
2019 Q3	$87K	Hold	252	–	–	﹤0.01%	984
2019 Q2	$232K	Hold	252	–	–	﹤0.01%	978
2019 Q1	$402K	Hold	252	–	–	﹤0.01%	912
2018 Q4	$471K	Hold	252	–	–	0.01%	865
2018 Q3	$594K	Sell	252 -16	-6%	-$49.5K	0.01%	820
2018 Q2	$923K	Sell	268 -43	-14%	-$132K	0.01%	761
2018 Q1	$883K	Hold	311	–	–	0.01%	749
2017 Q4	$801K	Buy	311 +2	+0.6%	+$5.69K	0.01%	741
2017 Q3	$878K	Buy	309 +86	+39%	+$227K	0.01%	763
2017 Q2	$527K	Buy	223 +139	+165%	+$275K	0.01%	818
2017 Q1	$213K	Hold	84	–	–	﹤0.01%	911
2016 Q4	$191K	Sell	84 -7	-8%	-$16.6K	﹤0.01%	943
2016 Q3	$228K	Sell	91 -1	-1%	-$2.98K	﹤0.01%	912
2016 Q2	$283K	Buy	+92	New	+$299K	﹤0.01%	756
2016 Q1	–	Sell	-64	Closed	-$330K	–	874
2015 Q4	$330K	Buy	+64	New	+$280K	0.01%	736

Other funds holding ACOR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Martingale Asset Management's ACOR Position: Q4 2019 in Review

Martingale Asset Management sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 252 shares — an estimated $87K sold.

Martingale Asset Management first reported a position in ACOR in Q4 2015 and held it in 15 quarters. The position peaked at $923K in Q2 2018. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

Martingale Asset Management reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
Martingale Asset Management sold 252 Acorda Therapeutics shares in Q4 2019, an estimated $87K.
Martingale Asset Management first reported a position in Acorda Therapeutics in Q4 2015 and held it in 15 quarters.
Martingale Asset Management's Acorda Therapeutics position peaked at $923K in Q2 2018.
121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on Martingale Asset Management's 13F filing for Q4 2019, filed 10 Feb 2020.